Spinraza’s flat sales rattle investors but Biogen sees momentum for key rare-disease therapy
April 24, 2018 at 12:12 PM EDT
The expensive rare disease therapy Spinraza has quickly become a critical part of Biogen’s performance, but the latest sales figures were sluggish.